Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: A systematic review and exploratory meta-analysis of placebo-controlled clinical trials

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Fornaro, Michele ^a   Stubbs, Brendon ^b,c   De Berardis, Domenico ^d   Perna, Giampaolo ^e   Valchera, Alessandro ^f   Veronese, Nicola ^g   Solmi, Marco ^g   Ganança, Licínia ^a,h  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^d Psychiatric Service of Diagnosis and Treatment Hospital G Mazzini   (Italy)

^e Department of Clinical Neurosciences   (Italy)

^f Hermanas Hospitalarias Villa San Giuseppe   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF LISBON   (Portugal)

Author keywords

Acute bipolar depression; Diagnostic and statistical manual for mental disorders fifth edition (DSM 5); Meta analysis; Mixed features; Second generation antipsychotic (SGA); Systematic review

Indexed keywords

ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; DATA ANALYSIS; DRUG EFFICACY; DSM-5; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; YOUNG MANIA RATING SCALE; CONTROLLED CLINICAL TRIAL (TOPIC); DEPRESSION; META ANALYSIS; PSYCHOLOGY;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CONTROLLED CLINICAL TRIALS AS TOPIC; DEPRESSION; HUMANS; TREATMENT OUTCOME;

EID: 84958554628     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020241     Document Type: Article

References (62)

1. Hayes, J.; Prah, P.; Nazareth, I.; King, M.;Walters, K.; Petersen, I.; Osborn, D. Prescribing trends in bipolar disorder: Cohort study in the United Kingdom THIN primary care database 1995-2009. PLoS ONE 2011, 6, e28725. [CrossRef] [PubMed].
2. Kendall, T. The rise and fall of the atypical antipsychotics. Br. J. Psychiatry 2011, 199, 266-268. [CrossRef] [PubMed].
3. Hooshmand, F.; Miller, S.; Dore, J.; Wang, P.W.; Hill, S.J.; Portillo, N.; Ketter, T.A. Trends in pharmacotherapy in patients referred to a bipolar specialty clinic, 2000-2011. J. Affect. Disord. 2014, 155, 283-287. [CrossRef] [PubMed].
4. Medici, C.R.; Videbech, P.; Gustafsson, L.N.; Munk-Jorgensen, P. Mortality and secular trend in the incidence of bipolar disorder. J. Affect. Disord. 2015, 183, 39-44. [CrossRef] [PubMed].
5. Bauer, M.; Glenn, T.; Alda, M.; Sagduyu, K.; Marsh, W.; Grof, P.; Munoz, R.; Severus, E.; Ritter, P.; Whybrow, P.C. Drug treatment patterns in bipolar disorder: Analysis of long-term self-reported data. Int. J. Bipolar Disord. 2013, 1. [CrossRef] [PubMed].
6. Carlborg, A.; Ferntoft, L.; Thuresson, M.; Bodegard, J. Population study of disease burden, management, and treatment of bipolar disorder in Sweden: A retrospective observational registry study. Bipolar Disord. 2015, 17, 76-85. [CrossRef] [PubMed].
7. Stubbs, B.; Vancampfort, D.; Solmi, M.; Veronese, N.; Fornaro, M. How common is bipolar disorder in general primary care attendees? A systematic review and meta-analysis investigating prevalence determined according to structured clinical assessments. Aust. N. Z. J. Psychiatry 2016. [CrossRef] [PubMed].
8. Berk, M.; Dodd, S.; Malhi, G.S. "Bipolar missed states": The diagnosis and clinical salience of bipolar mixed states. Aust. N. Z. J. Psychiatry 2005, 39, 215-221. [PubMed].
9. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 4th ed.; American Psychiatric Association: Washington, DC, USA, 1994; pp. 143-147.
10. Goldberg, J.F.; Perlis, R.H.; Bowden, C.L.; Thase, M.E.; Miklowitz, D.J.; Marangell, L.B.; Calabrese, J.R.; Nierenberg, A.A.; Sachs, G.S. Manic symptoms during depressive episodes in 1380 patients with bipolar disorder: Findings from the STEP-BD. Am. J. Psychiatry 2009, 166, 173-181. [CrossRef] [PubMed].
11. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; American Psychiatric Association: Washington, DC, USA, 2013.
12. McIntyre, R.S.; Soczynska, J.K.; Cha, D.S.; Woldeyohannes, H.O.; Dale, R.S.; Alsuwaidan, M.T.; Gallaugher, L.A.; Mansur, R.B.; Muzina, D.J.; Carvalho, A.; et al. The prevalence and illness characteristics of DSM-5-defined 'mixed feature specifier' in adults with major depressive disorder and bipolar disorder: Results from the International Mood Disorders Collaborative Project. J. Affect. Disord. 2014, 172C, 259-264. [CrossRef] [PubMed].
13. Perugi, G.; Angst, J.; Azorin, J.M.; Bowden, C.L.; Mosolov, S.; Reis, J.; Vieta, E.; Young, A.H.; Group, B.R.-I.-M.S. Mixed features in patients with a major depressive episode: The BRIDGE-II-MIX study. J. Clin. Psychiatry 2015, 76, e351-e358. [CrossRef] [PubMed].
14. Tohen, M.; Kanba, S.; McIntyre, R.S.; Fujikoshi, S.; Katagiri, H. Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J. Affect. Disord. 2014, 164, 57-62. [CrossRef] [PubMed].
15. Goldberg, J.F. Mixed depression: A farewell to differential diagnosis? J. Clin. Psychiatry 2015, 76, e378-e380. [CrossRef] [PubMed].
16. Hu, J.; Mansur, R.; McIntyre, R.S. Mixed specifier for bipolar mania and depression: Highlights of DSM-5 changes and implications for diagnosis and treatment in primary care. Prim Care Companion CNS Disord. 2014, 16. [CrossRef] [PubMed].
17. Prieto, M.L.; Ozerdem, A.; Quiroz, D.; Altinbas, K.; Aydemir, O.; Yalin, N.; Feeder, S.E.; Geske, J.R.; Frye, M.A. Exploratory factor analysis of mixed depression utilizing a modified version of Hypomania Checklist 32 (mHCL-32). Bipolar Disord. 2013, 15, 114.
18. Koukopoulos, A.; Sani, G.; Ghaemi, S.N. Mixed features of depression: Why DSM-5 is wrong (and so was DSM-IV). Br. J. Psychiatry 2013, 203, 3-5. [CrossRef] [PubMed].
19. Sani, G.; Vöhringer, P.A.; Napoletano, F.; Holtzman, N.S.; Dalley, S.; Girardi, P.; Ghaemi, S.N.; Koukopoulos, A. Koukopoulos' diagnostic criteria for mixed depression: A validation study. J. Affect. Disord. 2014, 164, 14-18. [CrossRef] [PubMed].
20. Judd, L.L.; Schettler, P.J.; Akiskal, H.; Coryell, W.; Fawcett, J.; Fiedorowicz, J.G.; Solomon, D.A.; Keller, M.B. Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes. J. Affect. Disord. 2012, 138, 440-448. [CrossRef] [PubMed].
21. Benazzi, F. Bipolar disorder-Focus on bipolar II disorder and mixed depression. Lancet 2007, 369, 935-945. [CrossRef].
22. Benazzi, F. A tetrachoric factor analysis validation of mixed depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32, 186-192. [CrossRef] [PubMed].
23. Swann, A.C. Activated depression: Mixed bipolar disorder or agitated unipolar depression? Curr. Psychiatry Rep. 2013, 15. [CrossRef] [PubMed].
24. Takeshima, M.; Oka, T. DSM-5-defined 'mixed features' and Benazzi's mixed depression: Which is practically useful to discriminate bipolar disorder from unipolar depression in patients with depression? Psychiatry Clin. Neurosci. 2015, 69, 109-116. [CrossRef] [PubMed].
25. Malhi, G.S.; Fritz, K.; Allwang, C.; Burston, N.; Cocks, C.; Harper, M.; Kearney, B.; Klug, P.; Meagher, L.; Mimnagh, J.; et al. Agitation for recognition by DSM-5 mixed features specifier signals fatigue? Aust. N. Z. J. Psychiatry 2015, 49, 499-501. [CrossRef] [PubMed].
26. Ghaemi, S.N. All mixed up: On the absence of diagnostic guidelines for mixed states in the ISBD Diagnostic Guidelines Task Force Report. Bipolar Disord. 2008, 10 (Pt 2), 129-130. [CrossRef] [PubMed].
27. Fornaro, M.; Aguglia, E.; Dell'Osso, L.; Perugi, G. Could the underestimation of bipolarity obstruct the search for novel antidepressant drugs? Expert Opin. Pharmacother. 2011, 12, 2817-2831. [CrossRef] [PubMed].
28. Goldberg, J.F.; Freeman, M.P.; Balon, R.; Citrome, L.; Thase, M.E.; Kane, J.M.; Fava, M. The American society of clinical psychopharmacology survey of psychopharmacologists' practice patterns for the treatment of mood disorders. Depress Anxiety 2015, 32, 605-613. [CrossRef] [PubMed].
29. McIntyre, R.S.; Cucchiaro, J.; Pikalov, A.; Kroger, H.; Loebel, A. Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: Post hoc analysis of a randomized placebo-controlled trial. J. Clin. Psychiatry 2015, 76, 398-405. [CrossRef] [PubMed].
30. Sherwood Brown, E.; Davila, D.; Nakamura, A.; Carmody, T.J.; Rush, A.J.; Lo, A.; Holmes, T.; Adinoff, B.; Caetano, R.; Swann, A.C.; et al. A randomized, double-blind, placebo-controlled trial of quetiapine in patients with bipolar disorder, mixed or depressed phase, and alcohol dependence. Alcohol. Clin. Exp. Res. 2014, 38, 2113-2118. [CrossRef] [PubMed].
31. Berk, M.; Tiller, J.W.; Zhao, J.; Yatham, L.N.; Malhi, G.S.; Weiller, E. Effects of asenapine in bipolar I patients meeting proxy criteria for moderate-to-severe mixed major depressive episodes: A post hoc analysis. J. Clin. Psychiatry 2015, 76, 728-734. [CrossRef] [PubMed].
32. Benazzi, F.; Berk, M.; Frye, M.A.; Wang, W.; Barraco, A.; Tohen, M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: A post hoc analysis. J. Clin. Psychiatry 2009, 70, 1424-1431. [CrossRef] [PubMed].
33. Patkar, A.; Gilmer, W.; Pae, C.U.; Vohringer, P.A.; Ziffra, M.; Pirok, E.; Mulligan, M.; Filkowski, M.M.; Whitham, E.A.; Holtzman, N.S.; et al. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PLoS ONE 2012, 7, e34757. [CrossRef] [PubMed].
34. Pae, C.U.; Patkar, A.A.; Gilmer, W.; Holtzman, N.; Thommi, S.B.; Ghaemi, S.N. Predictors of response to ziprasidone: Results from a 6-week randomized double-blind, placebo-controlled trial for acute depressive mixed state. Pharmacopsychiatry 2012, 45, 152-155. [CrossRef] [PubMed].
35. Clark, H.D.; Wells, G.A.; Huët, C.; McAlister, F.A.; Salmi, L.R.; Fergusson, D.; Laupacis, A. Assessing the quality of randomized trials: Reliability of the Jadad scale. Controll. Clin. Trials 1999, 20, 448-452. [CrossRef].
36. Wells, G.; Shea, B.; O'connell, D.; Peterson, J.;Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses; Ottawa Hospital Research Institute: Ottawa, ON, Canada, 2000.
37. Montgomery, S.A.; Asberg, M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 1979, 134, 382-389. [CrossRef] [PubMed].
38. Young, R.; Biggs, J.; Ziegler, V.; Meyer, D. A rating scale for mania: Reliability, validity and sensitivity. Br. J. Psychiatry 1978, 133, 429-435. [CrossRef] [PubMed].
39. Dunn, R.T.; Stan, V.A.; Chriki, L.S.; Filkowski, M.M.; Ghaemi, S.N. A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression. J. Affect. Disord. 2008, 110, 70-74. [CrossRef] [PubMed].
40. Malhi, G.S.; Fritz, K.; Allwang, C.; Burston, N.; Cocks, C.; Devlin, J.; Harper, M.; Hoadley, B.; Kearney, B.; Klug, P. Are manic symptoms that 'dip' into depression the essence of mixed features? J. Affect. Disord. 2016, 192, 104-108. [CrossRef] [PubMed].
41. De Berardis, D.; Marini, S.; Carano, A.; Lang, A.P.; Cavuto, M.; Piersanti, M.; Fornaro, M.; Perna, G.; Valchera, A.; Mazza, M.; et al. Efficacy and safety of long acting injectable atypical antipsychotics: A review. Curr. Clin. Pharmacol. 2013, 8, 256-264. [CrossRef] [PubMed].
42. Fornaro, M.; de Berardis, D.; Iasevoli, F.; Pistorio, M.L.; D'Angelo, E.; Mungo, S.; Martino, M.; Ventriglio, A.; Cattaneo, C.I.; Favaretto, E.; et al. Corrigendum to 'Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and 'therapeutic sensation seeking' in response towards subjective intolerance to pain' [J. Affect. Disord. 151 (2) (November 2013), 596-604]. J. Affect. Disord. 2014, 170C. [CrossRef].
43. Fornaro, M.; De Berardis, D.; Koshy, A.N.; Perna, G.; Valchera, A.; Vancampfort, D.; Stubbs, B. Prevalence and clinical features associated with bipolar disorder polypharmacy: A systematic review. Neuropsychiatr. Dis. Treat. 2016. in press.
44. Perugi, G.; Fornaro, M. Bipolar disorder treatment guidelines and their limits in every day clinical practice. G. Ital. Psicopatol. 2011, 17, 261-264.
45. Fornaro, M.; Giosuè, P. Current nosology of treatment resistant depression: A controversy resistant to revision. Clin. Pract. Epidemiol. Ment. Health 2010, 6, 20-24. [CrossRef] [PubMed].
46. Marneros, A.; Goodwin, F. Bipolar Disorders: Mixed States, Rapid Cycling and Atypical Forms; Cambridge University Press: Cambridge, UK, 2005.
47. Maj, M. "Mixed" depression: Drawbacks of DSM-5 (and other) polythetic diagnostic criteria. J. Clin. Psychiatry 2015, 76, e381-e382. [CrossRef] [PubMed].
48. Koukopoulos, A.; Sani, G. DSM-5 criteria for depression with mixed features: A farewell to mixed depression. Acta Psychiatr. Scand. 2014, 129, 4-16. [CrossRef] [PubMed].
49. Suppes, T.; Silva, R.; Cucchiaro, J.; Mao, Y.; Targum, S.; Streicher, C.; Pikalov, A.; Loebel, A. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. Am. J. Psychiatry 2015. [CrossRef] [PubMed].
50. Fornaro, M.; Martino, M.; De Pasquale, C.; Moussaoui, D. The argument of antidepressant drugs in the treatment of bipolar depression: Mixed evidence or mixed states? Expert Opin. Pharmacother. 2012, 13, 2037-2051. [CrossRef] [PubMed].
51. Roberts, R.J.; Lohano, K.K.; El-Mallakh, R.S. Antipsychotics as antidepressants. Asia Pac. Psychiatry 2015. [CrossRef] [PubMed].
52. Davey, J.; Turner, R.M.; Clarke, M.J.; Higgins, J.P. Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: A cross-sectional, descriptive analysis. BMC Med. Res. Methodol. 2011, 11. [CrossRef] [PubMed].
53. Kicinski, M.; Springate, D.A.; Kontopantelis, E. Publication bias in meta-analyses from the Cochrane Database of Systematic Reviews. Stat. Med. 2015, 34, 2781-2793. [CrossRef] [PubMed].
54. Stroup, D.F.; Berlin, J.A.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283, 2008-2012. [CrossRef] [PubMed].
55. Qi, X.; Yang, M.; Ren,W.; Jia, J.;Wang, J.; Han, G.; Fan, D. Find duplicates among the PubMed, EMBASE, and Cochrane Library Databases in systematic review. PLoS ONE 2013, 8, e71838.
56. Reuters, T. Endnote X7; Thomson Reuters: Philadelphia, PA, USA, 2013.
57. Hamilton, M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56-62. [CrossRef] [PubMed].
58. Carmody, T.J.; Rush, A.J.; Bernstein, I.; Warden, D.; Brannan, S.; Burnham, D.; Woo, A.; Trivedi, M.H. The Montgomery Asberg and the Hamilton ratings of depression: A comparison of measures. Eur. Neuropsychopharmacol. 2006, 16, 601-611. [CrossRef] [PubMed].
59. Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. Comprehensive Meta-Analysis Version 3; Biostat: Englewood, NJ, USA, 2005; p. 104.
60. Higgins, J.P.; Altman, D.G.; Gotzsche, P.C.; Juni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.; et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011, 343. [CrossRef] [PubMed].
61. Taylor, S.; Tweedie, R. A Non-Parametric 'Trim and Fill' Method of Assessing Publication Bias in Meta-Analysis; University of Colorado Health Sciences Center: Denver, FL, USA, 1998.
62. Roth, L.S. The DSM-V: Simplify, clarify. Psychiatry 2005, 2, 12-13. [PubMed].